Advertisement
Screener

Coherus Oncology, Inc. (CHRS) Total Long-Term Debt

2.8 / 5 stars · 68/120 Roast Me

Coherus Oncology, Inc. Total Long-Term Debt

Coherus Oncology, Inc. (CHRS) had Total Long-Term Debt of $73.66 million as of 2019-12-31, per its 10-Q filed 2020-05-07.

Discontinued › Balance Sheet › Liabilities

us-gaap:LongTermDebt · last filed 2020-05-07

  • 2019-12-31: Long-term Debt $73.66M.
  • 2019-06-30: Long-term Debt $73.29M.
  • 2019-03-31: Long-term Debt $73.12M.
  • 2018-12-31: Long-term Debt $0.00.
Period endLong-term Debt
2019-12-31$73.66M
10-Q · filed 2020-05-07
2019-06-30$73.29M
10-Q · filed 2019-08-05
2019-03-31$73.12M
10-Q · filed 2019-05-09
2018-12-31$0.00
10-Q · filed 2019-08-05

Similar stocks

Stock NameCountryMarket CapPE Ratio
Alpha Cognition Inc. (ACOG)$0.185B-6.77
PRECISION BIOSCIENCES INC (DTIL)United States$0.175B-3.95
Voyager Therapeutics, Inc. (VYGR)United States$0.173B-1.99
Protara Therapeutics, Inc. (TARA)United States$0.198B-3.22
Acumen Pharmaceuticals, Inc. (ABOS)United States$0.162B-1.83
Outlook Therapeutics, Inc. (OTLK)United States$0.162B-4.90
Compass Therapeutics, Inc. (CMPX)United States$0.204B-5.35
Humacyte, Inc. (HUMA)United States$0.155B-2.26
Alector, Inc. (ALEC)United States$0.213B-1.90
ANAVEX LIFE SCIENCES CORP. (AVXL)United States$0.218B-18.37